During the past decade, Champalimaud Cancer Center conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 3 clinical trials were completed, i.e. on average, 15% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 3 clinical trials were completed. i.e. 21.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Champalimaud Cancer Center" #1 sponsor was "Janssen Research & Development, LLC" with 5 trials, followed by "Becton, Dickinson and Company" with 2 trials sponsored, "Celgene" with 2 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 2 trials sponsored and "Kartos Therapeutics, Inc." with 2 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Champalimaud Cancer Center" #1 collaborator was "European Union" with 2 trials as a collaborator, "Borstkanker Onderzoek Groep" with 1 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "Cancer Trials Ireland" with 1 trials as a collaborator and "Centro Hospitalar De São João, E.P.E." with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Champalimaud Cancer Center" are "Multiple Myeloma" (3 trials), "Breast Cancer" (1 trials), "Breast Neoplasms" (1 trials), "Castration-Resistant Prostatic Cancer" (1 trials) and "Chronic Lymphocytic Leukemia" (1 trials). Many other conditions were trialed in "Champalimaud Cancer Center" in a lesser frequency.

Most popular intervention types in "Champalimaud Cancer Center" are "Drug" (15 trials), "Diagnostic Test" (2 trials), "Other" (2 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Dexamethasone" (3 trials), "Bortezomib" (2 trials), "Daratumumab" (2 trials) and "KRT-232" (2 trials). Other intervention names were less common.

The vast majority of trials in "Champalimaud Cancer Center" are 18 trials for "All" genders, 2 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Champalimaud Cancer Center". undefined are not yet recruiting, 11 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Champalimaud Cancer Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Champalimaud Cancer Center, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".